<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958629</url>
  </required_header>
  <id_info>
    <org_study_id>M2021098</org_study_id>
    <nct_id>NCT04958629</nct_id>
  </id_info>
  <brief_title>A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population</brief_title>
  <official_title>A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the prevalence and the prognosis in a corhort of patients with familial&#xD;
      hypercholesterolemia (FH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to achieve the following goals through prospective cohort study and&#xD;
      statistical analysis: (1) to determine the prevalence of familial hypercholesterolemia (FH)&#xD;
      in healthy people with hypercholesterolemia.（2) Compared with non FH population, the relative&#xD;
      risk of atherosclerotic cardiovascular disease (ASCVD) in FH patients in China was&#xD;
      calculated, and the risk prediction model of ASCVD in FH patients was constructed by using&#xD;
      biochemical results, imaging data, biomarkers and other indicators.（3) To evaluate the&#xD;
      benefits of different lipid-lowering strategies for FH patients in China.（4) To analyze the&#xD;
      gene carriers of FH patients in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Number of participants with atherosclerotic cardiovascular disease (ASCVD) events</measure>
    <time_frame>2 years from enrollmet</time_frame>
    <description>1) Fatal or non-fatal myocardial infarction; 2) Fatal or non-fatal ischemic stroke; 3) Coronary artery revascularization; 4) Peripheral artery revascularization; 5) Cardiogenic death</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>non-FH Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>FH Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>familial hypercholesterolemia</intervention_name>
    <description>Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.</description>
    <arm_group_label>FH Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hyperlipidemia were screened from health examination population. Among the&#xD;
        selected patients with hyperlipidemia, those who met the following inclusion and exclusion&#xD;
        criteria were included in the study cohort as FH group or non-FH group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) Patients with definite diagnosis of hyperlipidemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18.&#xD;
&#xD;
          2. Do not agree to participate in this study.&#xD;
&#xD;
          3. secondary hypercholesterolemia.&#xD;
&#xD;
          4. Phytosteronemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Gao, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Gao, Doctor</last_name>
    <phone>+86 13901366179</phone>
    <email>weigao@bjmu.edu.cn</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>familial hypercholesterolemia</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

